




Access and Global Health



Viatriis seeks to be a partner in building access at scale and more resilient healthcare systems. The core of our work lies in developing, sourcing, producing and distributing high-quality medicines to people around the world. The base of our business is a vast and diversified portfolio of generic medicines and trusted brands, serving an important role in making essential health products available and accessible, and preventing and treating some of the world's most pressing health conditions. We are also increasingly adding more innovative treatments to our portfolio, to further help address unmet needs.

Viatriis in 2024

Supplied high-quality medicines to ~1B patients around the world¹

Provided products that address the WHO's top 10 leading causes of death globally

Sold >80 billion doses of medicine across >165 countries and territories

Supplied medicines to ~90% of low- and lower-middle-income countries

Provided 50 products on the WHO Prequalification of Medicines List

Supplied >240 medicines on the WHO Essential Medicines List (EML), representing nearly 50% of the total list

Supplied >135 medicines on the WHO Essential Medicines List for Children, representing >35% of the total list

The Importance of a Global, Resilient Supply Chain to Access

We believe our global supply chain, with its breadth, resilience and established efficiencies, continues to be the best structure for maximizing supply availability and enabling access to medicines for patients, regardless of geography. No country makes every medicine it needs, and no medicine is made in every country.

A secure supply of medicines from multiple regions and countries around the world is more reliable and at less risk of being disrupted. Global, diverse and flexible supply chains are key to timely and affordable access to medicine.

As an essential business, Viatriis has taken actions to maintain a reliable supply of medicines, with special measures around critical medicines in times of volatile demand. Our ability to supply medicines and maintain high levels of service around the world is rooted in our global network of suppliers with a robust ability to manage shocks affecting any particular country or region. Our network allows us to offset risk and build resilience.

All Viatriis operations are covered by and expected to comply with statutory and regulatory requirements, such as current Good Manufacturing Practices (cGMP), Good Pharmacovigilance Practices (GPvP), Good Distribution Practices (GDP) and Good Clinical Practices (GCP) for all markets that they serve.

In 2024, we were able to maintain a global customer service level of 93% on time in full amid volatility in demand, inflation and supply chain disruptions in general.

Preventing and Managing NCDs

According to the WHO, NCDs are the leading cause of death globally, representing a significant burden to people and health care systems. As many as 18 million people die annually before the age of 70 from NCDs including cardiovascular disease, cancers, chronic respiratory diseases and diabetes – with a great majority of those deaths happening in low- or lower-middle-income countries.²

Viatri's broad portfolio of both off-patent and new, innovative medicines addresses many NCDs such as cardiovascular disease, diabetes, respiratory diseases, dermatology and ophthalmology.

Healthcare workers, especially those in primary care, are essential to improving the health and wellbeing of individuals and communities. They are often the first point of contact for people seeking healthcare services and key for people accessing the care they need. In 2024, we continued our dedicated work with partners across the world to empower healthcare workers to contribute to more resilient and healthier systems.

Our HCP Access Goal:

Goal: Impact 100 million patients via HCP education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025.*

Our Progress: More than 30,000 individuals have an NCD Academy account, an increase of more than 6,000 users in 2024 over the previous year. The total number of patients impacted since the launch of NCD Academy is ~115 million.¹

Fighting Infectious Disease

Viatri has a long history in the fight against infectious disease, which accounts for eight of the top 10 causes of death in low-income countries. We are working with global and local partners to help prevent infections, increase access to diagnosis and treatment, provide healthcare solutions and work on local manufacturing initiatives with partners to transfer technology to expand access where it is most needed.

- ▶ Viatri has more than 700 registrations of infectious disease products across low- and middle-income countries.
- ▶ Viatri has seven licensing agreements with the Medicines Patent Pool (MPP) for HIV (including PrEP), hepatitis C, and COVID-19. For ARV and infectious disease products, Viatri also has license agreements with Gilead, Viiv Healthcare, MSD, TB Alliance and Otsuka.
- ▶ Approximately 25% of the world's adults and >50% of the world's children on treatment for HIV use a Viatri product.

Our HIV Treatment Access Goal:

Goal: Provide ARV therapy equivalent to a total of 30 million patients, including >2 million children living with HIV/AIDS, between 2022 and the end of 2025.*

Our Progress: In 2024**, we provided treatments for ~7 million patients, including ~320,000 children living with HIV/AIDS. Since 2022, we have provided treatments for >24 million adults and children.

Collaborating to Address Antimicrobial Resistance

Antimicrobial resistance (AMR) is a significant global health challenge impacting millions of people around the world and with the potential to lead to even greater disruptions to care if not addressed. AMR threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi.

Viatri takes a multi-pronged approach to actively engaging in addressing AMR, both providing access through our portfolio of more than 90 antibiotics and in partnership with others, including as a founding member and active board member of the AMR Industry Alliance (AMRIA).

Supplied ~50% of medicines on the WHO EML anti-infective medicines section, and ~45% of medicines on the WHO EML for Children anti-infective medicines section.

Policy Engagement to Break Down Barriers to Access and Build Resilient Health Systems

Public policies are central factors in determining healthcare interventions and access to medicines and treatment. Viatri leverages our global experiences, scientific expertise and operations knowledge to support policymakers in identifying policies that advance access to quality medicines and build systems that sustain medicine availability while minimizing unintended consequences.

For more information, read the [Viatri 2024 Sustainability Report](#).

*Our ability to make progress on our goal depends on several factors, some of which are outside of our control, including the existence and funding of our distribution partners.

** The remediation activities at the Indore site have impacted our ARV therapy supply in 2024. We are aiming to be back on track by the end of 2025.

¹The number of patients served is an estimate calculated using internal sales data (global volume of doses sold in 2024 in all markets as aligned with IQVIA standard units), divided by estimated per patient usage, which is based on treatment dose, treatment duration, and treatment adherence as estimated by Viatri Medical Affairs based on approved label indication and instructions for use, current international guideline recommendations, and common usage in clinical practice. Patients using multiple Viatri medicines may be counted as multiple patients. Certain adjustments were applied to account for acceptable alternatives to the patient usage factors noted above, and rounded to the nearest hundred million. Estimates may be subject to reassessment.

²The calculation methodology for 2024 was updated to better reflect the cumulative patient impact of NCD Academy learners over multiple years. Under the prior year methodology, patient impact was calculated by multiplying the number of HCP learners by the average number of patients treated weekly (as self-reported by HCP learners upon registering for NCD Academy) by 50 working weeks. Using the prior year methodology, calculated patient reach would have been 92.5 million. For 2024, patient reach is now calculated at an individual HCP learner level by multiplying the number of patients treated per week, as self-reported by the individual HCP learner upon registering for NCD Academy by the number of weeks the individual was enrolled in NCD Academy (in some cases, multiple years). Patient reach for each individual learner is summed to arrive at total patient reach. Patient reach includes unique patients as well as repeat patient encounters.



[Viatri.com](#)



[LinkedIn](#)



[@ViatriInc](#)



[@ViatriInc](#)



[YouTube](#)



[Listen Well Podcast](#)